CEO of Juno Therapeutics brings deep knowledge of the biopharma
industry
SANTA CLARA, Calif.--(BUSINESS WIRE)--Jul. 18, 2017--
Agilent Technologies, Inc. (NYSE: A) today announced that Hans E.
Bishop, CEO of Juno Therapeutics, has been elected to its board of
directors.
Bishop co-founded Juno Therapeutics, a Seattle-based biopharmaceutical
company, in 2013. As president and CEO, Bishop leads Juno as it develops
cellular immunotherapies used in cancer treatment.
Under his leadership, the company went public in 2014 and has since
entered into a number of collaborations, delivering on key advances in
cellular immunotherapies for cancer treatment.
“Hans is an accomplished leader and extremely skilled at crafting
strategic vision, building teams and new businesses,” said Mike
McMullen, Agilent’s president and CEO. “He is well-known as a change
agent, who knows how to make things happen. His strong experience, and
expertise, especially in cancer immunotherapies and the broader
bio-pharmaceutical markets, will be extremely valuable as Agilent
continues to grow globally.”
“Hans is an outstanding addition to our board,” said Koh Boon Hwee,
Agilent chairman. “His talent, background and thoughtful personal style
are very well suited to our company. He understands the needs of our
customers, and will provide an important perspective with new insights
into our markets. I am pleased to welcome him to the board.”
Bishop has held a range of executive positions in the pharmaceutical
industry, including as COO at Dendreon, which launched the first
cellular immunotherapy for prostate cancer. Before that, he was
president of Specialty Medicine at Bayer Healthcare. He also served as
the global commercial head for Chiron Corp.
Bishop previously served on the board of Avanir Pharmaceuticals. He
graduated from Brunel University, U.K. with a BS in Chemistry.
“I have long admired Agilent’s scientific solutions, as well as its
strong customer focus and stellar reputation for integrity. I have
tremendous respect for Mike, Boon Hwee and the other board members, and
I am eager to begin working with them at this exciting time in the
company’s growth,” Bishop said.
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is a global leader in life sciences,
diagnostics and applied chemical markets. With more than 50 years of
insight and innovation, Agilent instruments, software, services,
solutions, and people provide trusted answers to its customers’ most
challenging questions. The company generated revenues of $4.20 billion
in fiscal 2016 and employs about 13,000 people worldwide. Information
about Agilent is available at www.agilent.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170718006466/en/
Source: Agilent Technologies Inc.
Agilent Technologies
Stefanie Notaney, +1 408-345-8955
+1 408
508-9369 - mobile
Stefanie.notaney@agilent.com